181 related articles for article (PubMed ID: 24113439)
1. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
[TBL] [Abstract][Full Text] [Related]
2. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
4. [proPSA: a precursor of prostate-specific antigen, may improve the early diagnosis of prostate cancer].
Sela BA; Doolman R
Harefuah; 2011 May; 150(5):466-9, 489. PubMed ID: 21678645
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
7. [Recent advances in proPSA on early detection in prostate cancer].
Zhu PY; Hong P; Huang YF
Zhonghua Nan Ke Xue; 2005 Dec; 11(12):944-6. PubMed ID: 16398372
[TBL] [Abstract][Full Text] [Related]
8. [Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients].
Houlgatte A; Vincendeau S; Desfemmes F; Ramirez J; Benoist N; Bensalah K; Durand X
Prog Urol; 2012 May; 22(5):279-83. PubMed ID: 22515924
[TBL] [Abstract][Full Text] [Related]
9. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
[TBL] [Abstract][Full Text] [Related]
10. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
[TBL] [Abstract][Full Text] [Related]
11. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis.
Filella X; Giménez N
Clin Chem Lab Med; 2013 Apr; 51(4):729-39. PubMed ID: 23154423
[TBL] [Abstract][Full Text] [Related]
14. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
[TBL] [Abstract][Full Text] [Related]
17. [[-2] proPSA: A Novel Marker of Prostate Cancer].
Ishikura K
Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Vukovic I; Djordjevic D; Bojanic N; Babic U; Soldatovic I
Int Braz J Urol; 2017; 43(1):48-56. PubMed ID: 28124526
[TBL] [Abstract][Full Text] [Related]
19. The prostate health index selectively identifies clinically significant prostate cancer.
Loeb S; Sanda MG; Broyles DL; Shin SS; Bangma CH; Wei JT; Partin AW; Klee GG; Slawin KM; Marks LS; van Schaik RH; Chan DW; Sokoll LJ; Cruz AB; Mizrahi IA; Catalona WJ
J Urol; 2015 Apr; 193(4):1163-9. PubMed ID: 25463993
[TBL] [Abstract][Full Text] [Related]
20. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination.
Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G
Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
